Rationale: Novel, evidence-based treatments are required for treatment-resistant post-
traumatic stress disorder (PTSD). 3, 4-Methylenedioxymethamphetamine (MDMA) has …

This multi-site, randomized, double-blind, confirmatory phase 3 study evaluated the efficacy
and safety of 3, 4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) versus …

Background Post-traumatic stress disorder (PTSD) is prevalent in military personnel and first
responders, many of whom do not respond to currently available treatments. This study …

Since the wars in Iraq and Afghanistan, posttraumatic stress disorder (PTSD) has become a
major area of research and development. The most widely accepted treatment for PTSD is …

Background: Pharmacological-assisted psychotherapies, using conventional and novel drug
agents, are increasingly being used both in clinical and experimental research settings …

Methylenedioxymethamphetamine (MDMA)–assisted psychotherapy for posttraumatic stress
disorder (PTSD) has been shown to significantly reduce clinical symptomatology, but …

Pharmacotherapy is often used to target symptoms of posttraumatic stress disorder (PTSD),
but does not provide definitive treatment, and side effects of daily medication are often …

We report follow-up data evaluating the long-term outcomes for the first completed trial of 3,
4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for chronic, treatment …

Post-traumatic stress disorder (PTSD) is a devastating psychiatric disorder afflicting millions
of people around the world. Characterized by severe anxiety, intrusive thoughts, pervasive …

Phase II trials of 3, 4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy
have demonstrated initial safety and efficacy for treatment of posttraumatic stress disorder …